SCHEMBL4696776

SCHEMBL4696776

CCOC(=O)C1CCN(C(=O)CC(C)(C)Sc2c(OC)cc(OC)cc2OC)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ATM Q13315 1/20 0.53
POLB P06746 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
GAA P10253 3/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 2/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 3/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697597 0.87 GAA (0.44) ALDH1A1MEN1KMT2AATMPOLB
SCHEMBL4693654 0.76 CYP1A2 (0.47) ALDH1A1MEN1KMT2AATMPOLB
SCHEMBL4754584 0.71 HSD17B10 (0.40) ALDH1A1SMN1; SMN2KDM4ETSHRTP53
SCHEMBL19195034 0.70 ALDH1A1 (0.61) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL12297020 0.68 ALDH1A1 (0.69) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL2607028 0.67 POLB (0.65) ALDH1A1MEN1KMT2APOLBGAA
SCHEMBL6983363 0.66 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL6983366 0.66 ALDH1A1 (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL1572674 0.65 MAPT (0.64) ALDH1A1MEN1KMT2APOLBGAA
SCHEMBL7400389 0.65 ALDH1A1 (0.66) ALDH1A1MEN1KMT2ASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109542-A4 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-03-26 EP disclosed
US-20050187222-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds NITROMED, INC. (US) 2005-08-25 US disclosed
US-6469065-B1 COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE NITROMED, INC. 2002-10-22 US disclosed
US-20020143007-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use GARVEY DAVID S (US) 2002-10-03 US disclosed
EP-1109542-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2001-06-27 EP disclosed
WO-2000012075-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187222-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds ADRB1, ADRB3, ADRA1D ALDH1A1 628/4885MEN1 3376/4885KMT2A 3871/4885
US-20020143007-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use ADRB1, ADRB3, ADRA1D ALDH1A1 610/4885MEN1 3390/4885KMT2A 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.